MALT1抑制剂和降解剂:针对NF-κB驱动的恶性瘤的策略
Ru-Yue Zhang1, Zi-Xuan Wang2, Meng-Yuan Zhang2
1Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China.
Journal of medicinal chemistry
|February 25, 2025
概括
粘膜相关的淋巴组织蛋白1 (MALT1) 对NF-κB依赖性癌症至关重要. 本综述详细介绍了MALT1抑制剂和降解剂,指导了针对癌症向治疗的未来药物开发.
科学领域:
- 生物化学和分子生物学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 粘膜相关淋巴组织蛋白1 (MALT1) 是一个关键的囊蛋白酶和酶.
- MALT1对于NF-κB依赖性恶性癌症的存活和扩散至关重要,包括MALT淋巴瘤和扩散性大B细胞淋巴瘤 (DLBCL).
- 失调的MALT1活性是各种恶性瘤的重要因素,使其成为关键的治疗点.
研究的目的:
- 为MALT1的结构和功能属性提供全面的概述.
- 总结一下针对MALT1.1的小分子抑制剂和降解剂开发的近期进展.
- 讨论化合物结构,结构-活性关系 (SAR) 分析以及MALT1向剂的生物活性.
主要方法:
- 对MALT1.1的结构和功能特征的文献综述.
- 对MALT1.1的小分子抑制剂和降解剂的最新进展进行分析.
- 对MALT1向化合物的结构-活性关系 (SAR) 和生物数据的检查.
主要成果:
- 阐明了MALT1在NF-κB信号通路中的作用及其对B细胞淋巴瘤的影响.
- 最近的小分子抑制剂和降解剂对MALT1.1表现出有前途的活性.
- SAR研究提供了关于优化MALT1向剂的效力,选择性和药用动力学特性的见解.
结论:
- MALT1是各种血液性恶性瘤的验证治疗标.
- 目前正在进行的小分子抑制剂和降解剂研究对MALT1向癌症治疗具有重大前景.
- 这一观点为未来的药物开发工作提供了一个框架,以提高MALT1向化合物的疗效和药物样性质.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


